How does thyroid disease affect anemia and iron‑deficiency anemia?

Thyroid Disease Significantly Impacts Anemia and Iron Deficiency Anemia Through Multiple Mechanisms

Thyroid dysfunction substantially increases the risk of anemia, with both hypothyroidism and hyperthyroidism associated with 1.2-1.8 times higher odds of having anemia compared to euthyroid individuals. 1 The relationship is bidirectional and clinically meaningful, affecting hemoglobin production, iron metabolism, and treatment response.

Magnitude of the Association

The evidence demonstrates clear quantitative relationships:

• Overt hypothyroidism increases anemia risk with an OR of 1.84 (95% CI 1.35-2.50) and lowers hemoglobin by approximately 0.22 g/dL 1, 2
• Subclinical hypothyroidism shows an OR of 1.21 (1.02-1.43) for prevalent anemia 1
• Overt hyperthyroidism carries an OR of 1.69 (1.00-2.87) 1
• Subclinical hyperthyroidism demonstrates an OR of 1.27 (1.03-1.57) 1

Recent prospective data from 2025 confirms that correction of thyroid dysfunction leads to significant improvement in hemoglobin values over 3 months of treatment 3, establishing causality beyond mere association.

Mechanisms Linking Thyroid Disease to Anemia

In Hypothyroidism

Iron deficiency is particularly prevalent in hypothyroid patients, especially women with Hashimoto's thyroiditis. 4 The mechanisms include:

• Impaired erythropoiesis: Thyroid hormones directly stimulate erythropoietin gene expression and production 3
• Reduced thyroid peroxidase (TPO) activity: Iron is essential for TPO function; deficiency creates a vicious cycle where low iron impairs thyroid hormone synthesis, which further compromises erythropoiesis 4
• Decreased iron absorption: Hypothyroidism reduces gastrointestinal motility and absorption capacity
• Epigenetic modifications: Iron deficiency may contribute to genomic changes promoting autoimmune thyroid disease 4

The 2024 cross-sectional study found that normocytic anemia is the most common type in hypothyroidism (38.64% of anemic patients), representing anemia of chronic disease, followed by microcytic anemia (19.32%) from iron deficiency, and macrocytic anemia (9.25%) from B12 deficiency 5.

In Hyperthyroidism

Excess thyroid hormones affect anemia through:

• Altered iron metabolism and increased oxidative stress 3
• Increased erythrocyte turnover exceeding compensatory production
• Hemolysis in severe cases

Clinical Implications for Diagnosis

When to Screen for Thyroid Disease in Anemic Patients

Screen all patients with unexplained anemia—particularly normocytic or refractory anemia—for thyroid dysfunction with TSH, free T3, and free T4. 3 This is especially critical in:

• Women of reproductive age with iron deficiency anemia
• Patients with anemia not responding to iron supplementation
• Those with symptoms overlapping hypothyroidism (fatigue, cold intolerance, weight changes)

When to Screen for Anemia in Thyroid Patients

Obtain a complete blood count at diagnosis and during routine follow-up of all thyroid disorder patients. 3 The evidence supports this as standard practice given the high prevalence of anemia in thyroid disease.

Interpreting Iron Studies in Thyroid Disease

A critical pitfall: ferritin levels up to 100 μg/L may still reflect iron deficiency in the presence of thyroid-related inflammation (similar to inflammatory bowel disease). 6 Consider transferrin saturation to clarify iron status when ferritin is in the 30-100 μg/L range.

The 2026 population study from Jordan demonstrated that individuals with iron deficiency and IDA had significantly lower FT3 and FT4 levels plus higher TSH compared to controls, with IDA patients showing higher prevalence of hypothyroidism (p=0.0011) 7.

Treatment Approach

Algorithmic Management Strategy

Step 1: Correct the thyroid dysfunction first

• Levothyroxine for hypothyroidism or antithyroid medication for hyperthyroidism
• Monitor response at 1 and 3 months with thyroid function tests AND hemoglobin 3

Step 2: Assess anemia type and severity

• Normocytic anemia (most common in hypothyroidism): Often improves with thyroid hormone replacement alone; represents anemia of chronic disease 5
• Microcytic anemia: Requires iron supplementation—oral iron 50-100 mg elemental iron daily (e.g., ferrous sulfate 200 mg once daily) 6
• Macrocytic anemia: Check B12/folate and supplement as needed 5

Step 3: Iron supplementation strategy in thyroid disease

• Start with oral iron unless contraindicated
• Critical consideration: Iron absorption may be impaired in hypothyroidism, similar to inflammatory bowel disease 6
• Consider IV iron if:
  • Hemoglobin <100 g/L with moderate-severe symptoms
  • Oral iron intolerance
  • No hemoglobin rise ≥10 g/L after 2 weeks of oral therapy 6
  • Severe villous atrophy (if concurrent celiac disease)

Step 4: Reassess at 3 months

• Expect hemoglobin improvement paralleling thyroid function normalization 3
• If anemia persists despite corrected thyroid function, investigate other causes (GI blood loss, B12/folate deficiency, chronic kidney disease)

Important Caveats and Pitfalls

Do not assume all anemia in thyroid patients is thyroid-related. While the association is strong, the British Society of Gastroenterology guidelines emphasize that even patients with known predisposing conditions (including endocrine disorders) warrant evaluation for GI causes of IDA, particularly those over 50 years 6. Approximately one-third of adults over 50 with IDA have underlying GI pathology, with one-third of those having malignancy.

Normocytic anemia in hypothyroidism may not respond to iron supplementation because it represents anemia of chronic disease rather than true iron deficiency 5. Avoid unnecessary iron therapy in these patients; focus on optimizing thyroid replacement.

The hemoglobin changes, while statistically significant, are modest (0.22 g/dL decrease in overt hypothyroidism) 2. However, the functional impact on quality of life can be substantial, particularly when combined with thyroid symptoms.

Subclinical thyroid dysfunction shows weaker associations with anemia development in prospective studies, with hazard ratios not reaching statistical significance 2. The decision to treat subclinical disease should not be based solely on anemia presence.

Integration with Broader Iron Deficiency Management

The provided guidelines focus primarily on GI causes of IDA 8, 6, but thyroid disease represents an important systemic modifier of iron metabolism that affects both absorption and utilization. Consider thyroid disease as part of the differential for refractory IDA or as a comorbidity requiring concurrent management rather than an alternative diagnosis.

For women with Hashimoto's thyroiditis specifically, adequate iron supplementation alongside iodine, selenium, and magnesium is considered a crucial element of effective therapy 4. The 2026 review emphasizes that iron serves as a cofactor for thyroid peroxidase and plays roles in hepatic detoxification and mitochondrial function, creating multiple points of intersection between iron and thyroid physiology 9.